Cellect Biotechnology: Clinical Trials

3 trials sponsored by Cellect Biotechnology, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 terminated. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Terminated 1, Unknown 1
Phase 21Unknown 1

Follow Cellect Biotechnology: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
ApoGraft - Acute Graft Versus Host Disease, Haploidentical Hematopoietic Stem Cell Transplant
Phase 1TerminatedWashington University School of Medicine42020-12-162023-05-19
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
non intervational - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
UnknownCellect Biotechnology122018-06-102019-11-26
Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation
Allogeneic MPBC transplantation from matched related donor - Hematological Malignancies
Phase 1 / Phase 2UnknownCellect Biotechnology122017-01-012019-11-26

Conditions studied

Autoimmune Lymphoproliferative Syndrome, Type IB (1)  ·  Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Countries

Israel (2)  ·  United States (1)

Top investigators

Mark Schroeder, M.D. (1)  ·  Tsila Zuckerman, MD (1)